Arquivo

Página 2/3 1 2 3

Zambon launches XADAGO® (SAFINAMIDE) in Belgium for patients with mid-to late stage Parkinson’s disease
04 abril 2016
Zambon and US Worldmeds partner to bring Newron Pharmaceuticals’ Parkinson’s disease treatment Xadago® (safinamide) to the U.S.
17 março 2016
Zambon launches Xadago® (Safinamide) in Italy for patients with mid- to late-stage Parkinson’s disease
29 fevereiro 2016
Zambon launches Xadago® (safinamide) in Spain for patients with mid-to late-stage Parkinson’s disease
22 fevereiro 2016
Zambon launches Xadago® (safinamide) in Switzerland for patients with parkinson’s disease
12 janeiro 2016
CHMP recommends Approval of Xadago TM (safinamide) to treat Parkinson´s disease in the EU
19 dezembro 2015
Zambon invests in innovation acquiring Eratech
06 agosto 2015
Zambon expands in Europe acquiring Nigaard
14 julho 2015
50 anos de Fluimucil (N-Acetilcisteína, NAC)
23 junho 2015
Zambon launches Xadago® (safinamide) for patients with mid- to late-stage Parkinson’s disease in Germany
15 maio 2015

Página 2/3 1 2 3

Notas de Imprensa

ZAMBON

PHARMA
Zambon SpA

FINE CHEMICALS
Zach System

RESEARCH VENTURE
Zcube

EUROPE

UK
Nordics

ASIA

SOUTH AMERICA

Ver más

Zambon Produtos Farmacêuticos, Lda. - ©2017, Todos os direitos reservados.
ZAMBON Prod. Farm., Lda. | Rua Comandante Enrique Maya, nº1 | 1500 - 192 Lisboa | Portugal | T. +351 217 600 952/4 | F. +351 217 600 975